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Prognosis for patients with estrogen-receptor (ER)-
negative basal breast cancer is poor, and chemo-
therapy is currently the best therapeutic option. We
have generated a compound-mutant mouse model
combining the activation of b-catenin and HGF
(Wnt-Met signaling), which produced rapidly growing
basal mammary gland tumors. We identified the che-
mokine system CXCL12/CXCR4 as a crucial driver of
Wnt-Met tumors, given that compound-mutant mice
also deficient in the CXCR4 gene were tumor resis-
tant. Wnt-Met activation rapidly expanded a popula-
tion of cancer-propagating cells, in which the two
signaling systems control different functions, self-
renewal and differentiation. Molecular therapy tar-
geting Wnt, Met, and CXCR4 in mice significantly
delayed tumor development. The expression of a
Wnt-Met 322 gene signature was found to be predic-
tive of poor survival of human patients with ER-nega-
tive breast cancers. Thus, targeting CXCR4 and its
upstream activators, Wnt and Met, might provide
an efficient strategy for breast cancer treatment.
INTRODUCTION
Breast cancer (BC) is a heterogeneous disease divided into
therapeutic groups, based on the estrogen receptor (ER) and
HER2/ErbB2 status (Figure S1A; van ’t Veer et al., 2002; Weigelt
and Reis-Filho, 2009). ER-negative basal breast cancers repre-
sent the most aggressive subtype with poor prognosis and a
lack of targeted therapies. The majority of ER-negative basal
breast cancers (70%) are triple negative for the ER, progester-
one receptor (PR), and HER2 (Carey et al., 2010). An additional
risk factor for developing basal breast cancer is the BRCA11214 Cell Reports 5, 1214–1227, December 12, 2013 ª2013 The Autgermline mutation (Foulkes et al., 2003). More recently, human
basal breast cancers have been shown to display high fre-
quencies of specific gene alterations, such as TP53, RB, and
PTEN mutations, overexpression of PI(3)KCA, WNT signaling
components, and MYC, as well as activating mutations of re-
ceptor tyrosine kinases, such as the EGFR, FGFR, IGFR1, and
MET (Carey et al., 2006; Shah et al., 2012; Cancer Genome
Atlas Network, 2012).
The relevance of Wnt/b-catenin signaling in breast cancer has
long been controversial. However, following molecular subclas-
sification, it is now clear that high expression of nucleocytoplas-
mic b-catenin, the hallmark of canonical Wnt signaling, is an
important clinical feature of basal breast cancers and is predic-
tive for poor overall survival (Geyer et al., 2011; Khramtsov et al.,
2010; Lo´pez-Knowles et al., 2010). Mutations of b-catenin
encoding the amino-terminal domain have been observed in
92% of patients with metaplastic carcinomas, a distinct group
of basal breast cancers (Hayes et al., 2008). Knockdown of
the gene for the Wnt receptor FZD7 in basal breast cancer
cell lines reduced the expression of Wnt target genes and in-
hibited tumor growth in mice (Yang et al., 2011). Ectopic expres-
sion of genes encoding inhibitory Wnt ligands, such as sFRP1,
in breast cancer cell lines, can bind and effectively competed
with FZD receptors, reducing the ability of these cells to form
mammary gland tumors in mice (Matsuda et al., 2009). The
tyrosine kinase receptor Met and its ligand, hepatocyte growth
factor/scatter factor (HGF/SF), have also been described to be
associated with basal breast cancers and correlate with poor
patient outcome (Gastaldi et al., 2010; Gherardi et al., 2012).
High Met overexpression was consistently associated with
coexpression of basal markers, cytokeratin 5, cytokeratin 6,
caveolin 1, c-Kit, and p63, thus assigning Met as an additional
constituent of the basal breast cancer phenotype (Garcia
et al., 2007).
Breast cancer can be modeled in mice carrying mutations or
transgenes. For instance, conditional mutations of Brca1 and/or
p53 in mammary gland epithelial cells induced mammary glandhors
tumors in mice that displayed characteristics of human basal
breast cancer (Bouwman et al., 2010; Shafee et al., 2008).
Remarkably, a genome-wide screen revealed amplifications of
the Met locus in 73% of Brca1/p53-deficient mouse tumors,
indicating that Met signaling is crucial for the generation of basal
mammary gland tumors (Smolen et al., 2006). Expression of
activating mutations of MET in mice, or overexpression of
HGF induced histologically diverse mammary gland tumors,
among them tumors that resemble human basal breast cancer
(Graveel et al., 2009; Ponzo et al., 2009; Knight et al., 2013;
Gallego et al., 2003). Similarly, activation of the Wnt signaling
system, either by overexpression of Wnt ligands or by gain-of-
function mutations of b-catenin and APC mutations resulted in
formation of mammary gland neoplasias. The type of tumors
ranged from squamous metaplasias to adenocarcinomas de-
pending on the particular model, which also varied in the degree
or the time point of activation of the signals (Monteiro et al.,
2013; Imbert et al., 2001; Nusse and Varmus, 1982; Michaelson
and Leder, 2001; Miyoshi et al., 2002). Moreover, Wnt/b-catenin
signals can cooperate with other oncogenic signaling systems
to promote the development of aggressive carcinomas (Malan-
chi et al., 2008; Vermeulen et al., 2010), but in breast cancer
models such cooperation has not been assessed by genetic
means.
In the present study, we modeled rapid basal breast cancer
formation in mice by combining activating mutations of Wnt/
b-catenin and HGF/Met in mammary gland epithelial cells using
the pregnancy-induced Whey Acidic Protein (WAP) promoter.
We identified a gene signature of murine Wnt-Met tumors, which
was found to predict poor survival of human patients harboring
ER-negative, basal breast cancer types. Furthermore, by gene
expression profiling and genetic means, the chemokine system
CXCL12/CXCR4 was found to be controlled by Wnt and Met in
an intricate manner. Our study also suggests that combination
therapies targeting CXCR4 and its upstream activators, Wnt
and Met, might thus be beneficial for patients with basal breast
cancer.
RESULTS
Activation ofWnt/b-Catenin andHGF/Met Signalingwith
the WAP Promoter in Mice Induces Basal Mammary
Gland Tumors
To assess the potential role of the cooperation of Wnt/b-catenin
and HGF/Met signaling during mammary gland tumorigenesis,
we generated compound-mutant mice coexpressing activating
mutations in these signaling systems. Gain-of-function b-catenin
mutant mice (carrying a floxed allele of exon 3 of b-catenin,
recombined by WAP-cre, which is expressed in the mammary
gland of pregnant and postpartum mice) were crossed with
mice that overexpressed the Met ligand HGF under the control
of the WAP promoter (WAP-cre;b-cateninex3/+;WAP-HGF or
WAP-cre;b-catnex3/+;HGF; referred to as compound Wnt-Met
mutant mice; see the Experimental Procedures and Supple-
mental Experimental Procedures) (Harada et al., 1999; Gallego
et al., 2003; Miyoshi et al., 2002). Protein expression of WAP
and b-catenin was strongly induced during pregnancy, and cre
recombinase was detected in early to late postpartum animalsCell Re(Figures S1B and S1C). Transgene and cre expression was
almost absent in virgin mice; however, the combined activation
of b-catenin and HGF in mammary glands induced precocious
lobuloalveolar hyperplasia (Figure S1D, bottom, marked by
arrows). Two weeks postpartum, the majority of compound
Wnt-Met mutant mice presented with palpable tumors in each
mammary gland (Figures 1A and 1B), and in few cases virgin
mice also developed small tumors (Figure 1C). Tumor onset in
the compound Wnt-Met mutants was rapid compared to sin-
gle-mutant mice, which remained tumor free 30 days post-
partum or longer (Figure 1B). Histological analysis revealed
that compound-mutant tumors appearing after 2 weeks post-
partum exhibited a mixed phenotype; areas resembling basaloid
hyperplasia and squamous metaplasia (Figure 1D). Single HGF
and b-catenin mutant mice have been previously described to
develop adenosquamous carcinomas and squamous meta-
plasia, respectively, but these tumors were only observed 4
and 12 months postpartum (see also Gallego et al., 2003;
Miyoshi et al., 2002). Analysis of tumor tissue from Wnt-Met
compound-mutant mice demonstrated strong expression of
nucleocytoplasmic b-catenin, relative to single mutants or wild-
type mice (Figure S1E, left, bottom, marked by arrows). Further-
more, production of the milk protein b-casein after pregnancy
could not be detected in Wnt-Met compound-mutant mice,
indicating a block in normal mammary gland differentiation
(Figure S1E, right, bottom). Next, we performed transcription
profiling of compound-mutant tumors and compared the gene
signature with signatures of tumors in previously analyzed
mouse models (Herschkowitz et al., 2007). In unsupervised
cluster analysis, the expression profile of b-catnex3-HGF mutant
tumors grouped closely with the profiles of basal tumors
induced byWnt1 overexpression, Brca1+/;Trp53+/ mutations,
or dimethylbenzanthracene treatment, but were more distinct
from luminal tumors induced by PyMT, Neu, andMyc (Figure 1E).
The transcription profile also revealed that compound-mutant
tumors were triple negative for HER2/ErbB2, ER, and PR.
Genes encoding keratin 5, 14, keratin 17, and collagens, i.e.,
components of basal tumors, were highly upregulated, whereas
expression levels of Claudin 3 and 7 and the luminal genes
Notch, Hey1, and Xpa1 were low. Moreover, quantitative
RT-PCR (qRT-PCR) and immunofluorescence analyses
confirmed that compound Wnt-Met mutant tumors exhibited
basal characteristics; i.e., high levels of basal and myoepithelial
markers (K5, K14, and SMA) were expressed throughout
the tumor, whereas luminal cell markers (K8, K18, and E-
cadherin) were present at low levels (Figure 1F, top; Figure 1G).
Further, the expression of Wnt target genes and stem cell
markers Lrp6, Lrp5, and Axin2 were increased (Figure 1F,
middle) (http://www.stanford.edu/group/nusselab/cgi-bin/wnt/
target_genes) (Holland et al., 2013). The expression of several
metastasis-associated genes such as Twist1, Cxcr4, and Postn
were upregulated in Wnt-Met compound tumors, indicating that
these tumors display invasive properties and may have the
potential to metastasize (Figure 1F, bottom). Altogether, com-
bined activation of Wnt and Met in the adult murine mammary
gland induces rapid formation of aggressive tumors that exhibit
a morphological, gene, and protein expression profile charac-
teristics of basal breast cancers.ports 5, 1214–1227, December 12, 2013 ª2013 The Authors 1215
Figure 1. Combined b-Catenin and HGF Activation by the WAP Promoter Drives Rapid Mammary Gland Tumor Formation in Mice
(A and B) Visual examination and quantification of tumor development in single and compound (WAP-cre;b-catnex3/+;HGF) mutants. (A) Single- and compound-
mutant mice and explanted tumors examined at 2 weeks postpartum (the scale bar represents 1 cm).
(B) Kaplan-Meier curve showing tumor-free survival period for single- and compound-mutant mice.
(C) Numbers of compound-mutant mice displaying tumors (black) during mammary gland development.
(D) Hematoxylin and eosin (H&E)-stained sections of compound-mutant tumors 2 weeks postpartum.
(E) Heatmap depicting a hierarchical clustering of gene expression of compound-mutant tumors (red) compared to previously reported basal and luminal mouse
tumors (Herschkowitz et al., 2007).
(F) qRT-PCR analysis of compound-mutant tumors for differentiation markers (top), canonical Wnt target genes (middle), and metastasis-inducing genes
(bottom). Data are shown as fold change compared to control (error bars represent ±SEM, n = 3).
(G) Immunofluorescent staining for K8 luminal and K5 basal cell markers in single- versus compound- mutant tumor tissue.
Magnification, 403.Canonical Wnt Signaling Controls Self-Renewal,
whereas Met Signaling Suppresses Differentiation in
Tumor Cells
To assess the individual contribution of Wnt and Met signaling
to mammary gland tumorigenesis, isolated epithelial cells from
compound Wnt-Met mutant tumors were treated with small1216 Cell Reports 5, 1214–1227, December 12, 2013 ª2013 The Autmolecular weight inhibitors, and gene expression profiling was
performed with Affymetrix microarrays (Figure 2A). The com-
pound ICG-001 interferes with binding of b-catenin to the CBP
cofactor, which is important for Wnt-dependent proliferation
and target gene expression (Emami et al., 2004), whereas PHA
665752 acts asATP-competitive inhibitor that blocks the tyrosinehors
Figure 2. Self-Renewal of Tumor Cells Is Regulated by Activated b-Catenin, whereas Dedifferentiation depends on Activated Met
(A) Compound-mutant tumor cells treated with PHA 665752 (1 mM), ICG-001 (25 mM) or a control, and changes in gene expression analyzed by Affymetrix arrays.
Shown is a heatmap depicting the expression of genes regulated by Wnt/b-catenin or HGF/Met signaling; yellow represents downregulation.
(B) Detailed heatmap showing regulated genes implicated in signaling, self-renewal, and differentiation after PHA 665752 or ICG-001 treatment (genesmarked by
red arrows were further characterized in C).
(C) qRT-PCR validation of regulated genes after inhibitor treatment. Data are shown as fold change compared to control (error bars represent ±SEM, n = 3).
(D) Compound-mutant tumor cells were treated with a combination of PHA 665752 (1 mM) and ICG-001 (25 mM), or a control, and changes in gene expression
were analyzed with Affymetrix arrays. Shown are the top synergistically regulated gene set following combined inhibitor Wnt and Met treatment (Cxcl12 is boxed
in red) (see also Figure S2D).kinase activity of the Met receptor (Christensen et al., 2003) (see
Figure S2A for chemical structures of the compounds). A heat-
mapof unsupervised cluster analysis identified genesdownregu-
lated individually by ICG-001 (338 genes) or PHA 665752 (68
genes), and common genes downregulated by the two inhibitors
(34 genes) (Figures 2A and S2B). Remarkably, Wnt signaling
controlled the expression of genes essential for proliferation
and self-renewal, e.g., Birc5, Top2a, Hells, and Aurkb (DiMeo
et al., 2009), whereas Met signaling regulated the expression ofCell Regenes important for epithelial differentiation, Krt6b, Krt14, Vegfc,
Cxcr4, and Gata3 (Lim et al., 2010) (Figure 2B, marked by red
arrows; confirmation by qRT-PCR is in Figure 2C; summarized
in Figure S2C). The genes regulated by both Wnt and Met
included components of TGF-b, insulin, and receptor tyrosine
kinase signaling, for instance, Ltbp2, Igf1, and Ret (Figure 2B).
These data suggest that the two individual signaling pathways
drive independent biological programs: Wnt signaling may regu-
late self-renewal, whereas Met may control differentiation.ports 5, 1214–1227, December 12, 2013 ª2013 The Authors 1217
Figure 3. Wnt-Met Mammary Gland Tumors Require CXCR4/
CXCL12 Signaling
(A) Kaplan-Meier curve depicting tumor-free survival period in triple com-
pound-mutant mice lacking CXCR4 (WAP-cre; b-catnex3;HGF;CXCR4ex2/ex2)
1218 Cell Reports 5, 1214–1227, December 12, 2013 ª2013 The AutWe also examined the effect of combining ICG-001 and PHA
665752 inhibitor treatment in the Wnt-Met mammary gland
tumor cells by gene expression profiling. Genes that were mini-
mally or not affected by single inhibitors (<2-fold change; p <
0.005) but responded synergistically (>2.5-fold change; p <
0.005) to the inhibitor combination are displayed in a heatmap
(Figure S2D; see also a gene ontology-term enrichment analysis
using DAVID) (Figure S2E) (Huang et al., 2009). Remarkably, 322
genes clustered into a ‘‘synergistic’’ group, i.e., they were
deregulated more strongly by the combination of inhibitors
compared to the single inhibitors, hereafter referred to as the
‘‘Wnt-Met gene signature’’ (Figure S2D). Among the genes with
significant synergistic changes in gene expression, many have
been implicated in mammary gland biology and breast cancer,
like Agtr2, Col11a1, Igf1, Prl3a1, Aldh1a1, and Cxcl12 (Fig-
ure S2D, marked in red on the right) (Maxwell, 2010), and others
are known to function in Wnt signaling, like Sfrp1, Dkk3, and
Bambi (http://www.stanford.edu/group/nusselab/cgi-bin/wnt/
target_genes). Agtr2 and Col11a1 are regulated specifically by
the combination of inhibitors, whereas Cxcl12 was mildly regu-
lated by the Wnt inhibitor and more strongly by the combination
ofWnt andMet inhibitors (Figure 2D,Cxcl12 is highlighted in red).
Because the Cxcl12 receptor Cxcr4 is regulated by Met (see
Figures 2B, 2C, and S3A), the changes in expression of the che-
mokine and its receptor suggest a mode of autocrine signaling
during Wnt-Met-driven basal mammary gland tumor formation.
Wnt-Met Mammary Gland Tumors Require
CXCR4/CXCL12 Signaling
To investigate the potential role of CXCL12/CXCR4 chemokine/
receptor signaling on Wnt-Met-driven tumor formation, we used
mouse genetics to conditionally ablate the Cxcr4 gene, i.e.,
through deletion of the essential exon 2 (Nie et al., 2004) in the
mammary gland tissue in compound-mutant mice (WAP-cre;
b-catnex3/+;HGF;CXCR4ex2/ex2, referred to as triple-mutant mice)
(Figure S3A). Strikingly, the appearance of tumors was signifi-
cantly delayed in triple-mutant mice, compared to Wnt-Met mu-
tants,whereas tumor growth in triplemutantswith only one floxed
Cxcr4 allele was unaffected (Figure 3A). The weight of mammary
gland tissues, an indicationof tumor size,was6-fold lower in triple
than in double mutant mice 2 weeks postpartum (Figure 3B).shown in black, compared to compound-mutant mice with a heterozygous
allele of CXCR4 (WAP-cre; b-catnex3;HGF;CXCR4+/ex2) shown in orange,
compared to compound-mutant mice containing thewild-type allele of CXCR4
(WAP-cre;b-catnex3/+;HGF) shown in red.
(B) Mammary gland tumor weight fromWnt-Met compound- and triple-mutant
mice 2 weeks postpartum.
(C) H&E staining of compound double- and triple-mutant tumors examined
2 weeks postpartum.
(D) Structure of the 50 end of the CXCL12 gene containing three predicted
LEF-TCF binding sites, P11 being composite, and ChIP in MDA MB431 cells
using these DNA sequences and anti-b-catenin. ICG-001 and CHIR99021
treatments were performed to show specificity of canonical Wnt signaling.
Myc and Axin2 sequences are confirmed binding sites. Error bars
represent ±SEM, n = 3.
(E) Kaplan-Meier survival plots showing four distinct CXCL12 expression
groups across 3,547 breast cancer patients with relapse-free survival (RFS)
data.
hors
Remarkably, the histology of triple-mutant mammary glands at
2–5 weeks postpartum contained areas that resembled normal
mammary glands (Figure 3C, bottom). At 7 weeks, triple-mutant
mice developed tumors; however, these late stage tumors re-ex-
pressed CXCR4, indicating a subset of tumor cells that had
escaped cre recombination (Figure S3B). Overall, these genetic
findings highlight the importance of CXCR4 signaling in Wnt-
Met-driven mammary gland tumor formation.
Gene expression data indicated that CXCL12 is a Wnt target
and moreover is controlled synergistically by Wnt and Met (Fig-
ure 2D). We performed in silico analysis of potential TCF/LEF
binding sites on the promoter and 50 regions of the CXCL12
gene using the PATCH 1.0 program, which was followed by
chromatin immunoprecipitation (ChIP) in human breast cancer
MDA-MB-231 cells. Three potential TCF/LEF binding regions
were found in the CXCL12 gene, and one of them contained
three consecutive TCF/LEF consensus sequences (scheme in
Figure 3D, top). ChIP was performed to confirm these as poten-
tial binding sites for b-catenin/TCF/LEF complexes. Both anti-
b-catenin and anti-LEF1 could enrich the three TCF/LEF binding
sites, and the enrichment was comparable to those observed
with TCF/LEF binding sites in the promoters of c-Myc and
Axin2, two well-characterized canonical Wnt target genes (Fig-
ure 3D, bottom; Figure S3C) (http://www.stanford.edu/group/
nusselab/cgi-bin/wnt/target_genes). ICG-001 reduced the
abundance of b-catenin on these TCF/LEF binding sites,
whereas the Wnt activator CHIR99021 led to enhancement.
Neither ICG-001 nor CHIR99021 treatment influenced LEF1-
binding to these sites. These results demonstrate that CXCL12
is a direct Wnt/b-catenin target gene in mammary gland cancer
cells. We also compared the expression levels of CXCL12 with
the survival of human breast cancer patients. Kaplan-Meier
analysis was performed on data obtained from 3,597 patient tu-
mors from 21 public data sets, which revealed that CXCL12
expression levels significantly correlated with patients survival
(analyzed in four different quartiles, p = 2.2E-18) (Figure 3E and
Table S1). We conclude from these data (1) that the compound
Wnt-Met-driven mammary gland tumors are dependent on
CXCR4 signaling, (2) that CXCL12 is a direct Wnt target gene,
which (3) is further synergistically regulated by Wnt and Met,
and (4) the expression levels of theCXCL12 gene can predict dis-
ease outcome in breast cancer patients.
The Mouse Wnt-Met Gene Signature Predicts Disease
Outcome in Human Breast Cancer Patients
We analyzed whether the mouse Wnt-Met gene signature con-
sisting of 322 genes (see Figure S2D) can predict clinical
outcome in human breast cancer patients. Data obtained from
3,597 patient tumors from 21 public data sets were grouped
based on breast cancer subtypes and analyzed by hierarchical
clustering using the expression of the Wnt-Met gene signature
(see also Experimental Procedures and Supplemental Experi-
mental Procedures) (Gyo¨rffy and Scha¨fer, 2009). The Wnt-Met
gene signature could be used to subgroup the main subtypes
of breast cancers, i.e., basal, HER2/ErbB2, and luminal A and
B subtypes (Figure 4A; colored area enlarged in Figure S4).
Next, retrospective Kaplan-Meier survival analyses were per-
formed from patient data of basal (n = 624), luminal A (n =Cell Re1,609), luminal B (n = 757), and HER2/ErbB2 (n = 607) breast
cancers, using the expression of the murine Wnt-Met gene
signature. Remarkably, high expression of the Wnt-Met signa-
ture correlated to a shorter relapse-free survival (RFS) time in hu-
man patients with ER-negative basal and HER2/ErbB2 breast
cancers (Figure 4B, left, p = 3.6E-06 and p = 2.3E-05, respec-
tively; note that 31% of HER2/ErbB2 tumors were ER negative),
but not in luminal A and B cancer types (Figure 4B, right). We
conclude from these data that high expression level of themouse
322 Wnt-Met signature genes predicts poor survival of human
patients with ER-negative basal breast cancers.
Combinations of Wnt, Met, and CXCR4 Inhibitors Delay
Tumor Formation in Mice
We performed therapy experiments to test whether targeting
Wnt, Met, and CXCR4 in the genetic mouse model of basal
breast cancer could reduce tumor burden. The combination of
Wnt and Met inhibitors ICG-001 and PHA 665752 or the small
molecule inhibitor AMD3100, a competitive antagonist of the
CXCR4 receptor (Nimmagadda et al., 2010), were administered
in Wnt-Met mutant mice postpartum at regular intervals over
24 days (Figure 5A). The compounds were tested at several con-
centrations (PHA 665752 at 25 and 50 mg/kg; ICG-001 at 200
and 100 mg/kg; and AMD3100 at 1, 5, and 10 mg/kg), which dis-
played little effect on body weight, indicating minimal toxicity
(Figures S5A–S5C, left graphs; see also the Experimental Proce-
dures). Animals treated with either ICG-001 or PHA 665752 ex-
hibited a moderate decrease in mammary gland tumor volume;
however, treatment with the combination of ICG-001 and PHA
665752 or with AMD3100 strongly suppressed tumor onset up
to 16 days (Figure 5B, red and blue curves; Figures S5A–S5C,
right graphs). Tumor relapse was observed following prolonged
treatments, although this was significantly delayed in mice
treated with the combination of ICG-001 and PHA 665752.
Further inhibitor combinations were examined revealing the
strongest inhibition in tumor size after triple treatment using
AMD3100, ICG-001 plus PHA 665752 (Figure 5C). The use of
AMD3100 in combination with ICG-001 and PHA 665752 also re-
vealed the most significant delay in tumor onset (Figure 5D), with
the smallest tumors (0.1 cm3) palpable at 24 days of treatment.
Histological analyses of mammary gland tumors in untreated an-
imals revealed basaloid hyperplasia and squamous metaplasia
(see also above); however, treatment with PHA 665752 affected
squamous differentiation, which was more pronounced with
ICG-001 treatment because mammary glands structures re-
mained largely hyperplastic (Figure 5E, top, quantified in the
graph below). Strikingly, the combination of the inhibitors
ICG-001 plus PHA 665752, AMD3100 and triple combinations
resulted in the appearance of alveolar glandular structures, indi-
cating epithelial cell differentiation (Figure 5E, bottom pictures,
graph below; Figure S5D). Tumor histology revealed distinct
areas resembling normal mammary gland tissue in mice treated
with all three compounds, which could be confirmed by K8/K5
and b-casein staining (Figures S5E and S5F). Bromodeoxyuri-
dine (BrdU) pulse-labeling experiments revealed decreased
proliferation in K5-positive epithelial cells after treatment with
ICG-001, ICG-001 plus PHA 665752, AMD3100, or AMD3100
plus ICG-001 plus PHA 665752 (Figure 5F, quantified below).ports 5, 1214–1227, December 12, 2013 ª2013 The Authors 1219
Figure 4. The Wnt-Met Gene Signature Predicts
Survival of Human Breast Cancer Patients
(A) The mouse 322 intrinsic Wnt-Met gene set shows
predictive power for the molecular subtypes of human
breast cancer, shown in a heatmap.Molecular subtypes of
breast cancer, which have been described previously,
were divided into cohorts according to their clinical char-
acteristics (lymph node status and grade) and molecular
subtypes. Red represents a basal cell gene cluster, orange
represents a HER2/ErbB2 gene cluster, blue represents a
luminal A gene cluster, and green represents a luminal B
gene cluster.
(B) Kaplan-Meier survival plots of four subgroups of breast
cancer patients with RFS time, using the 322 Wnt-Met
mouse gene set (BA, basal; HER, HER2; LA, luminal; A, LB,
luminal B; LO, lymph node negative; L1, lymph node
positive; G, grade).Taken together, treatment with a combination of Wnt andMet in-
hibitors, with the CXCR4 inhibitor, or with triple treatments signif-
icantly delayed tumor onset, suppressed proliferation and
induced differentiation of the Wnt-Met tumors.1220 Cell Reports 5, 1214–1227, December 12, 2013 ª2013 The AuthorsWnt and Met Signaling Cooperate to
Maintain Cancer-Propagating Cells
We wanted to confirm on the cellular level that
Wnt, Met, andCXCR4 signaling regulate distinct
biological functions in the adult mammary gland
tumor cells, as suggested by gene expression
profiling (see Figures 2B and 2C). Mammary
gland tissues from the different mouse model
genotypes were enzymatically digested to
obtain single cells and subjected to endothelial
and hematopoietic cell depletion for the enrich-
ment of epithelial cells (Figure S6A). Flow
cytometric analysis using antibodies against
CD24 and CD29 surface markers (Shackleton
et al., 2006; Stingl et al., 2006) separated three
major cell populations in single-mutant tissues:
a CD24+/CD29high enriched mammary stem
cell (MaSC) subpopulation, a CD24high/CD29+
luminal progenitor and mature cell population,
and aCD24low/CD29+ fraction containing a stro-
mal cell/mixed compartment (Figure 6A, top). In
contrast, compound Wnt-Met tumors at 1 week
postpartum displayed expansion of a cell popu-
lation that we define as CD24+/CD29medium cells
(37.7%, encircled in red) (Figure 6A, lower left).
When CD24+/CD29medium and CD24low/CD29+
cells were cultured for 7 days as mammo-
spheres, CD24+/CD29medium cells were highly
enriched, and the CD24low/CD29+ cells that
correspond to a stromal population were largely
depleted (Figure 6A, lower right). Cultured tumor
cells of compound Wnt-Met tumors maintained
the expression of both transgenes after 14 days
in culture, as confirmed by YFP-Cre and HGF
expression (Figure S6B). In addition, tumor cells
were profiled using the combination of CD24and CD49f surface markers, which revealed an expansion of
CD24+/CD49fhi subpopulation in the Wnt-Met compound-
mutant tissue (Figure 6B, lower left). Analysis using other cell-
surface markers such as Sca1+, ALDH, or CD61 did not reveal
heterogeneity of the CD24+/CD29medium tumor cell populations.
These data demonstrate that combined activation of Wnt and
Met signaling promotes the expansion of a population of cells
with progenitor and stem cell characteristics, which is further
supported by mammosphere culture assays (see also below).
qRT-PCR analysis could confirm transgene expression in iso-
lated tumor cells from the different mouse models (Figure 6C).
To assess the tumorigenic potential of CD24+/CD29medium
cells isolated from 1 week postpartum Wnt-Met mammary
glands, compared to CD24+/CD29high mammary gland cells
from 1 week postpartum single mutants, the cell populations at
different dilutionswere transplanted into clearedmammary gland
fat pads of NOD/SCID/IlR2/mice (Figure S6A, right) (Quintana
et al., 2008). Remarkably, as few as 100 CD24+/CD29medium cells
from compound Wnt-Met mutant mice were able to generate
tumor outgrowths 4 weeks posttransplantation, indicating that
these cells harbor cancer-propagating capacity (Figure 6D,
bottom left). In contrast, 50,000 of unsorted cells were required
for tumor formation (Figure 6D, upper left). Transplantation of
CD24+/CD29high cells from single-mutant mice, even at the high-
est injection numbers, did not result in tumor outgrowths (Fig-
ure 6D, right). Histological analysis revealed that tumors derived
from transplanted CD24+/CD29medium cells were indistinguish-
able from the original tumors, i.e., were mixed tumors, demon-
strating that this pool of cancer-propagating cells retained their
ability to form complex tumors (Figure 6E, compare with Fig-
ure 1D). Additionally, we used a fluorescent reporter mouse ex-
pressing YFP to perform lineage tracing of transplanted tumor
cells and could show that YFP+ cells gave rise to tumors, which
expressed luminal and basal differentiation markers, K8 and
K5, respectively (Figure S6C). These results demonstrate that
combined Wnt-Met signaling expands a population of cells that
demonstrate a strong cancer-propagating ability.
The self-renewal properties of mammary gland epithelial cells
from mice with different genotypes were measured by mammo-
sphere formation in culture, i.e., growth in suspension in serum-
free media (Figure S6A, left) (Dontu et al., 2003). After 7 days in
culture, the number and size of mammospheres generated
from Wnt-Met compound-mutant tumors were increased 5- to
6-fold in comparison to controls (Figure S6D, quantified in Fig-
ure S6E). To further address the function of Wnt, Met, and
CXCR4 signaling on self-renewal, mammosphere formation
was assessed in the presence of pharmacological inhibitors.
Remarkably, mammospheres treated with the Wnt inhibitor
ICG-001 or b-catenin siRNAs were significantly reduced in size
and number (Figure 6F, left; quantifications in Figures 6G, S6F,
and S6G). In contrast, suppression of Met or CXCR4 by pharma-
cological inhibitors or siRNAs had minor effects on mammo-
sphere formation (Figure 6F, left; quantifications Figures 6G,
S6F, and S6G). Next, we examined the differentiation capacities
of cells derived from the different genotypes by growth in semi-
solid 3D Matrigel (Figure S6A, middle) (Lee et al., 2007). CD24+/
CD29high cells derived from wild-type and single-mutant mam-
mary glands produced hollow acini-like structures composed
of a polarized layer of epithelial cells encapsulating a lumen,
whereas CD24+/CD29medium cells from compoundWnt-Met mu-
tants produced filled structures, which continued to expand
rapidly (Figure S6H; quantification in Figure S6I). Remarkably,Cell Retreatment of the CD24+/CD29medium cells from double mutants
with the Met or CXCR4 inhibitors (PHA 665752 or AMD 3100)
for 14 days transformed filled structures into hollow acini with
a polarized outer epithelial layer that resembled structures
formed by control and single-mutant CD24+/CD29high cells (Fig-
ure 6F, middle; quantification in Figure 6H). Differentiation
induced by blocking Met and CXCR4 signaling could be
confirmed by the expression of the epithelial cell markers K8/
K5 (Figure 6F, right). In contrast, the Wnt inhibitor ICG-001 had
no major effect on the morphology of the filled structures formed
in 3D Matrigel, although sphere size was moderately reduced.
Thus, the two signaling systems Wnt and Met indeed control
distinct properties of mammary gland tumor cells, self-renewal
byWnt on one side, and block of differentiation andmorphogen-
esis by Met on the other. The chemokine receptor CXCR4 regu-
lates similar cellular properties as Met, i.e., induces block of
differentiation and morphogenesis.
DISCUSSION
In an adult murine model of breast cancer, we could show that
genetic activation of both Wnt/b-catenin and HGF/Met signaling
using the pregnancy-induced WAP promoter, induced fast-
growing basal mammary gland tumors. We found that enhanced
chemokine/receptor CXCL12/CXCR4 signaling is an important
driver of tumor formation, because mutation in the Cxcr4 gene
induced resistance to tumorigenesis. In Wnt-Met mutant mice,
combination therapies with small molecule Wnt, Met, and
CXCR4 inhibitors yielded significant reduction in tumor develop-
ment. Furthermore, we could show that a mouseWnt-Met signa-
ture of 322 genes predicted disease outcome in human basal
breast cancer patients. Thus, our data suggest that Wnt, Met,
and CXCR4-regulated genes are valuable biomarkers in patients
with basal breast cancer, and these patients may benefit
from treatment using combinations of Wnt, Met, and CXCR4
inhibitors.
The coactivation of Wnt/b-catenin and HGF/Met signaling in
mouse adult mammary gland epithelium was performed under
the control of the WAP promoter. The WAP promoter is active
in stem cells and luminal cells present during pregnancy and
lactation, i.e., in lobuloalveolar progenitor cells (Wagner et al.,
1997). The activation of b-catenin and HGF in mouse mammary
glands produced hyperplastic alveolar nodules, which formed
tumors resembling features described for other basal mammary
gland tumors (Herschkowitz and Lubet, 2010); however,
compared to the other mouse models, the compound Wnt-Met
mice developed tumors extremely rapidly. Thus, our data indi-
cate that the combination of Wnt and Met signaling in the adult
mammary gland rapidly expands a population of stem or lobu-
loalveolar progenitor cells that display cancer-propagating cell
properties. The two signaling systems in mousemammary gland
tumors control distinct biological functions that cooperate in
tumor formation, promotion of self-renewal and inhibition of dif-
ferentiation. Gene expression profiling supported the concept
that Wnt signaling contributes mainly to proliferation and self-
renewal, because important cell-cycle checkpoint, proliferation,
and self-renewal genes were deregulated. Further, Wnt signaling
strongly promoted self-renewal in the mammosphere assay,ports 5, 1214–1227, December 12, 2013 ª2013 The Authors 1221
(legend on next page)
1222 Cell Reports 5, 1214–1227, December 12, 2013 ª2013 The Authors
which enriches for cancer-propagating cells (Dontu et al., 2003).
This is in line with other reports, which demonstrate that Wnt1,
Wnt3a, and Wnt10b can support self-renewal and regenerative
capacities of mammary gland stem cells and cancer stem cells
(Shackleton et al., 2006; Zeng and Nusse, 2010; Holland et al.,
2013; Wend et al., 2013). A role for Wnt signaling in the self-
renewal of cancer-propagating/cancer stem cells has been pro-
posed for several other tumor types (Clevers, 2011; Holland
et al., 2013). In contrast, high Met activity in mammary gland tu-
mor cells affected mainly differentiation. This was notable in 3D
Matrigel cultures, where tumor cells reformed alveolar structures
subsequent to Met inhibition. Gene expression profiling sup-
ported the role of Met in differentiation, because genes modu-
lating epithelial differentiation were controlled by Met activity.
In other cellular contexts, Met can also control growth andmigra-
tion of tumor cells (Gherardi et al., 2012). The question arises as
towhich cells may represent the cell of tumor origin in compound
Wnt-Met mice. Previous lineage-tracing experiments using
WAP-cre identified luminal cells capable of resisting apoptosis
during involution and clonally expand upon the succeeding preg-
nancy to give rise to luminal and alveolar cells. These cells were
therefore described as alveolar progenitors or parity-induced
cells (Wagner et al., 2002). More recently, lineage tracing of the
mammary gland using inducible cre expressed either in myoepi-
thelial cells (K14- or K5-expressing cells) or in luminal cells (K8-
or K18-expressing cells) demonstrated that the mammary gland
initially develops from multipotent embryonic K14-expressing
progenitors, which give rise to both myoepithelial cells and
luminal cells. However, postnatal mammary gland development
that occurred during puberty, as well as mammary gland expan-
sion that accompanied pregnancy, confirmed the presence of
two types of long-lived stem cells (Van Keymeulen et al., 2011).
Our experiments therefore indicate that in the Wnt-Met com-
pound-mutant model lobuloalveolar progenitor cells are
expanded and, when transplanted into fat pads of immune-defi-
cient mice, can give rise to complex tumors displaying cancer-
propagating cell characteristics. Thus, our data support the
notion that a multi- or bipotent progenitor cell population repre-
sents the target of oncogenic transformation driven by Wnt and
Met in the adult mammary gland.
Compound Wnt-Met-driven tumors express the chemokine
receptor CXCR4, which is required for Met-dependent suppres-
sion of differentiation. During metastasis, CXCR4 and the che-
mokine CXCL12 control the migration of tumor cells from sites
of primary growth (Holland et al., 2006; Zlotnik et al., 2011).
Our data provide genetic evidence that CXCR4 signaling is a
crucial step downstream of Wnt andMet activation during mam-Figure 5. Therapy with a Combination of Wnt and Met or CXCR4 Inhib
(A) Scheme showing the time course of inhibitor treatment in Wnt-Met compoun
(B) Tumor volume in compound-mutant mice after inhibitor treatment with 25 mg
10 mg/kg AMD 3100 (s.c.). n = 10 mice per group.
(C) Comparison of Wnt-Met compound tumor volume at day 18 after the differen
(D) Tumor volume in compound-mutant mice after combined inhibitor treatment
665752 (10 mg/kg, 25 mg/kg), AMD 3100 plus ICG-001 (10 mg/kg, 100 mg/kg), an
n = 6 mice per group.
(E) H&E staining of tumors treated with the indicated inhibitors; bottom left, quant
(F) BrdU staining in tumors treated with different inhibitors; BrdU (yellow), K5 (red),
day 16. (ip, intraperitoneal injection; iv, intravenous injection; sc, subcutaneous i
Cell Remary gland tumorigenesis, as tumor development does not
occur when CXCR4 is mutated. Moreover, inhibition of CXCR4
signaling using the AMD3100 small molecule antagonist in-
hibited tumor growth in therapy experiments of mice and
strongly induced tumor cell differentiation in mice and Matrigel
cultures. The fact that ablation and inhibition of CXCR4 suffice
to reverse many biological effects of activated Wnt and Met
signaling highlights the importance of CXCL12/CXCR4 as func-
tional targets. CXCR4 has been described as a Met target in
breast cancer cells in recent studies using pharmacological
interference (Huang et al., 2012; Matteucci et al., 2007), which
is in accordance to our genetic and expression data. Moreover,
Wnt and Met activity synergistically activated CXCL12 expres-
sion, and theChIP experiments on cultured human breast cancer
cells indicated that CXCL12 is a direct Wnt/b-catenin target
(see model in Figure S7). Overall, our study thus demonstrates
that production of CXCL12 and autocrine activation of its recep-
tor CXCR4 are hallmarks of Wnt-Met-driven adult mammary
gland cancers.
Wnt-Met compound-mutant mice were treated with Wnt, Met,
and CXCR4 inhibitors or a combination of inhibitors. Remark-
ably, combined treatment with all three inhibitors strongly sup-
pressed the emergence of mammary gland tumors in compound
mutants, and in major areas the presence of differentiated
normal ductal structures was observed. In vivo, all inhibitors
and inhibitor combinations affected tumormorphology, although
to varying extents. Differences seen on self-renewal/differentia-
tion are clearly distinguishable in vitro; however, this ismore diffi-
cult to distinguish in vivo, whichmay be due to additional factors,
e.g., tumor-stroma interaction. Intense efforts are made world-
wide to develop potent inhibitors of Wnt/b-catenin signaling,
but only few of these are already assessed in clinical trials (Taka-
hashi-Yanaga and Kahn, 2010). An improved version of the
ICG-001 used here is presently in clinical trial for leukemia
(Wend et al., 2013). Similarly, strategies to inhibit HGF/Met
signaling are currently being evaluated in clinical trials, with
promising results (Gherardi et al., 2012). A few of these inhibitors
have been suggested to preferentially target cancer-propagating
cells, which are often resistant to conventional cancer treat-
ments like chemotherapy and radiation (Gherardi et al., 2012;
Holland et al., 2013; Zhang et al., 2010). We found that the com-
bination of Wnt and Met inhibitors had profound effects on
endogenous tumors, and our experiments on sorted tumor cells
indicate that these inhibitors targeted not only the bulk of the
tumor but preferentially cancer-propagating cells. Combinations
of Wnt and Met inhibitors can be examined in the future, for
instance, in therapy experiments of human tumor xenograftsitors Delays Tumor Formation in Compound-Mutant Mice
d-mutant mice.
/kg PHA 665752 (i.v.), 100 mg/kg ICG-001 (i.p.), the combination of the two, or
t inhibitor treatment combinations.
with PHA 665752 plus ICG-001 (25 mg/kg, 100 mg/kg), AMD 3100 plus PHA
d AMD 3100 plus PHA 665752 plus ICG-001 (10 mg/kg, 25 mg/kg, 100 mg/kg).
ification of tumor morphology in compound mutants after different treatments.
K8 (green), and DAPI (blue); bottom left, quantification of BrdU incorporation at
njection).
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in animal models. AMD3100, a compound that targets the
Wnt-Met-driven CXCR4/CXCL12 signaling system, has been
examined clinical trials in patients with lymphomas or multiple
myelomas (Keating, 2011) but not in trials for solid tumors. We
have also found that combinations of the three inhibitors, against
Wnt, Met, and CXCR4, are the most effective in delaying tumor
onset. Overall, our findings encourage the use of combinations
of Wnt, Met, and CXCR4 inhibitors for therapies directed against
cancer-propagating cells of solid tumors.
We have also shown that the mouse Wnt-Met gene signature
can be used to distinguish human breast cancer subtypes in
several aspects. Remarkably, the overall expression of 322
signature genes identified in the mouse tumors is predictive for
poor survival of patients with ER-negative breast cancers, i.e.,
in basal and HER2/ErbB2 but not in luminal A and B subtypes.
The data therefore suggest that the mouse Wnt-Met signature
may be used as prognostic indicator in cancer patients. We
also demonstrate here that high expression of one of the syner-
gistically regulated Wnt-Met target gene, CXCL12, correlates
with poor prognosis in human breast cancer patients. Other
gene expression tools like Mammaprint and Oncotype Dx are
now used worldwide in clinical settings, and their application
improved treatment strategies (Oakman et al., 2010). It is
conceivable that the Wnt-Met signature described here, or a
number of selected genes thereof, can be used to further
improve stratification of breast cancers, in particular, those
cancers that do not respond to hormonal therapy. Moreover,
such an analysis could identify patients that might benefit from
a treatment with a combination of Wnt and Met inhibitors, or
treatment combinations with CXCR4 inhibitors. Collectively,
our results suggest that the analysis of Wnt and Met expression
and target genes in basal breast cancer may serve as useful
biomarkers to predict patient prognosis and suggest new thera-
peutic options.EXPERIMENTAL PROCEDURES
Mouse Strains
All animal experiments were conducted in accordance with national, Euro-
pean, and internal MDC regulations. WAP-cre, b-catnex3/b-catn+, WAP-HGF,
and CXCR4flox/flox mice have been described (Gallego et al., 2003; Harada
et al., 1999; Nie et al., 2004). All crossings were performed in FVB/N miceFigure 6. Wnt and Met Signaling Cooperate in Distinct Functions in Or
(A) Flow cytometric analysis of CD24/CD29 surface marker expression in cells pr
cells from compound mutants 1 week postpartum that were grown 7 days in mam
population of cells from compound-mutant tumors.
(B) Flow cytometric analysis of CD24/CD49f surface expression from single- and
(C) qRT-PCR analysis for transgene expression (b-cateninex3 and HGF) in isolated
mutant mice.
(D) Generation of tumors following transplantation of sorted and unsorted cells in
CD24+/CD29medium/hi and unfractionated cells of single- and double-mutant tumo
formed).
(E) H&E stainings showing histological images from the original tumor and from t
(F) Mammosphere (left) and 3D Matrigel (middle) aggregate formation using iso
mammary glands, in the presence and absence of inhibitors. Matrigel cultures (righ
with DAPI. Error bars represent ±SEM, n = 6.
(G) Quantification of the number and size of mammospheres from the experimen
(H) Quantification of the number of filled and hollow 3D Matrigel organoids from
Cell Refor at least ten generations. After one round of pregnancy, phenotypes were
analyzed in each of the models.
Mammosphere and 3D Matrigel Assays and Inhibitor Treatments
Mammosphere assays are described in the Supplemental Information. For 3D
Matrigel assays, cells were plated in 25% Matrigel in MAM-media on top of
an agarose layer. Pharmacological inhibitors ICG-001 (10 mM), PHA665752
(1 mM), and AMD 3100 (1 mM) were added to either Mammosphere or 3D
Matrigel cultures and were supplemented every 3 days. Mice were administra-
tion with 25 mg/kg PHA 665752 (intravenously [i.v.]), 100 mg/kg ICG-001
(intraperitoneally [i.p.]), the combination of the two, or 10 mg/kg AMD 3100
(subcutaneously [s.c.]) three times per week for 4 weeks.
Mammary Fat Pad Transplantation Assays
Transplantations of cells into cleared mammary gland fat pads were carried
out as described (Deome et al., 1959) using 3-week-old NOD/SCID/ILR2/
immunodeficient mice.
In Vivo Treatment of Wnt-Met Compound-Mutant Mice with
Inhibitors
Early postpartum animals were injected with single doses or combinations
of PHA 665752 (25 mg/kg i.v.), ICG-001 (100 mg/kg i.p.), AMD 3100
(i.v., 10 mg/kg), or control for 22–24 days, three times per week. Tumor burden
was monitored and measurements were taken several times per week.
Individual tumor volumes (V) were calculated using the formula V = (length 3
[width]2)/2.
Microarray and Bioinformatic Analysis
For details, see the Supplemental Information.
ACCESSION NUMBERS
The GenBank accession number for the microarray expression data is
GSE35899.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and one table and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2013.11.001.
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